Typical antipsychotic

Jump to: navigation, search

WikiDoc Resources for Typical antipsychotic

Articles

Most recent articles on Typical antipsychotic

Most cited articles on Typical antipsychotic

Review articles on Typical antipsychotic

Articles on Typical antipsychotic in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Typical antipsychotic

Images of Typical antipsychotic

Photos of Typical antipsychotic

Podcasts & MP3s on Typical antipsychotic

Videos on Typical antipsychotic

Evidence Based Medicine

Cochrane Collaboration on Typical antipsychotic

Bandolier on Typical antipsychotic

TRIP on Typical antipsychotic

Clinical Trials

Ongoing Trials on Typical antipsychotic at Clinical Trials.gov

Trial results on Typical antipsychotic

Clinical Trials on Typical antipsychotic at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Typical antipsychotic

NICE Guidance on Typical antipsychotic

NHS PRODIGY Guidance

FDA on Typical antipsychotic

CDC on Typical antipsychotic

Books

Books on Typical antipsychotic

News

Typical antipsychotic in the news

Be alerted to news on Typical antipsychotic

News trends on Typical antipsychotic

Commentary

Blogs on Typical antipsychotic

Definitions

Definitions of Typical antipsychotic

Patient Resources / Community

Patient resources on Typical antipsychotic

Discussion groups on Typical antipsychotic

Patient Handouts on Typical antipsychotic

Directions to Hospitals Treating Typical antipsychotic

Risk calculators and risk factors for Typical antipsychotic

Healthcare Provider Resources

Symptoms of Typical antipsychotic

Causes & Risk Factors for Typical antipsychotic

Diagnostic studies for Typical antipsychotic

Treatment of Typical antipsychotic

Continuing Medical Education (CME)

CME Programs on Typical antipsychotic

International

Typical antipsychotic en Espanol

Typical antipsychotic en Francais

Business

Typical antipsychotic in the Marketplace

Patents on Typical antipsychotic

Experimental / Informatics

List of terms related to Typical antipsychotic

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Typical antipsychotics (sometimes referred to as conventional antipsychotics, classical neuroleptics or major tranquilizers) are a class of antipsychotic drugs first developed in the 1950s and used to treat psychosis (in particular, schizophrenia), and are generally being replaced by atypical antipsychotic drugs. Typical antipsychotics may also be used for the treatment of acute mania, agitation, and other conditions. The first typical antipsychotics to enter clinical use were the phenothiazines.

High-potency and low-potency

Traditional antipsychotics are broken down into low-potency and high-potency classifications:

Potency Examples Side effects
high-potency fluphenazine and haloperidol more extrapyramidal side effects (EPS) and less histaminic (e.g. sedation), alpha adrenergic (e.g. orthostasis) and anticholinergic (e.g. dry mouth)
low-potency chlorpromazine less EPS but more H1, alpha1, and muscarinic

Depot injections

Some of the high-potency antipsychotics have been formulated as the decanoate ester (e.g. fluphenazine decanoate) to allow for a slow release of the active drug when given as a deep, intramuscular injection. This has the advantage of providing reliable dosing for a person who doesn't want to be drugged. Depot injections can also be used for involuntary community treatment patients to ensure compliance with a community treatment order when the patient would refuse to take daily oral medication. Depot preparations were limited to high-potency antipsychotics so choice was limited . It is therefore preferable to use oral medications if the cooperation and compliance of the patient can be assured.

The oldest depots available were haloperidol and fluphenazine, with flupentixol and zuclopenthixol as more recent additions. All have a similar, predominantly extrapyramidal, side effect profile though there are some variations between patients. More recently a long acting preparation of the atypical antipsychotic risperidone has become available, offering a new choice. Risperidone still has a higher incidence of extrapyramidal effects than some other drugs available however.

Common side effects

Side effects vary among the various agents in this class of medications, but common side effects include: dry mouth, muscle stiffness, muscle cramping, tremors, EPS and weight-gain. EPS is a cluster of symptoms consisting of parkinsonism, dystonias, and akathisia. Anticholinergics such as benztropine and diphenhydramine are commonly prescribed to treat the symptoms of EPS.

Risks of serious side effects

There is a significant risk of the serious condition tardive dyskinesia developing as a side effect of typical antipsychotics. The risk of developing tardive dyskinesia after chronic typical antipsychotic usage varies on several factors, such as age and gender. The commonly reported incidence of TD among younger patients is about 5% per year. Among older patients incidence rates as high than 20% per year have been reported. The average prevalence is approximately 30%.[1] There are no treatments that have consistently been shown to be effective for the treatment of tardive dyskinesias, however branched chain amino acids, melatonin, and vitamin E have been suggested as possible treatments. The atypical antipsychotic clozapine has also been suggested as an alternative antipsychotic for patients experiencing tardive dyskinesia. Tardive dyskinesia may reverse upon discontinuation of the offending agent or it may be irreversible.

Neuroleptic malignant syndrome, or NMS, is a rare, but potentially fatal side effect of antipsychotic treatment. NMS is characterized by fever, muscle rigidity, autonomic dysfunction, and altered mental status. Treatment includes discontinuation of the offending agent and supportive care.

The role of typical antipsychotics has come into question recently as studies have suggested that atypical antipsychotics may increase the risk of death in elderly patients. A retrospective cohort study from the New England Journal of Medicine on Dec. 1, 2005 showed an increase in risk of death with the use of typical antipsychotics that was on par with the increase shown with atypical antipsychotics.[2] This has led some to question the common use of antipsychotics for the treatment of agitation in the elderly, particularly with the availability of alternatives such as mood stabilizing and antiepileptic drugs.

Typical medications

See also

References

  1. Llorca PM, Chereau I, Bayle FJ, Lancon C (2002). "Tardive dyskinesias and antipsychotics: a review". Eur. Psychiatry. 17 (3): 129–38. PMID 12052573.
  2. Wang PS, Schneeweiss S, Avorn J; et al. (2005). "Risk of death in elderly users of conventional vs. atypical antipsychotic medications". N. Engl. J. Med. 353 (22): 2335–41. doi:10.1056/NEJMoa052827. PMID 16319382.

sv:Typiska antipsykotika


Linked-in.jpg